Andere Kunden interessierten sich auch für
![Accelerating the Development of New Drugs and Diagnostics]( "Accelerating the Development of New Drugs and Diagnostics")
Accelerating the Development of New Drugs and Diagnostics43,99 €![Advancing Gene-Targeted Therapies for Central Nervous System Disorders]( "Advancing Gene-Targeted Therapies for Central Nervous System Disorders")
Advancing Gene-Targeted Therapies for Central Nervous System Disorders69,99 €![International Regulatory Harmonization Amid Globalization of Drug Development]( "International Regulatory Harmonization Amid Globalization of Drug Development")
International Regulatory Harmonization Amid Globalization of Drug Development43,99 €![Ethical and Scientific Issues in Studying the Safety of Approved Drugs]( "Ethical and Scientific Issues in Studying the Safety of Approved Drugs")
Ethical and Scientific Issues in Studying the Safety of Approved Drugs59,99 €![Strengthening a Workforce for Innovative Regulatory Science in Therapeutics Development]( "Strengthening a Workforce for Innovative Regulatory Science in Therapeutics Development")
Strengthening a Workforce for Innovative Regulatory Science in Therapeutics Development34,99 €![Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System]( "Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System")
Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System23,99 €![Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders]( "Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders")
Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders18,99 €
The Institute of Medicine (IOM) Forum on Neuroscience and Nervous System Disorders, in collaboration with the IOM Forum on Drug Discovery, Development, and Translation, convened a workshop on January 20-21, 2015, to explore policy changes that might increase private sector investment in research and development innovation that fills unmet medical needs for central nervous system (CNS) disorders. Workshop participants strategized about how to incentivize companies to fortify their CNS drug development programs, shrinking obstacles that currently deter ventures. Representatives from academia, government agencies, patient groups, and industry gathered to share information and viewpoints, and to brainstorm about budget-neutral policy changes that could help widen the pipeline toward drugs that address unmet needs for CNS disorders. This report summarizes the presentations and discussion of the workshop.